Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology

Overview
This study develops a fully murine CD105 CAR-T cell system to study CAR-T biology in immunocompetent mice. It also validates a human CD105 CAR against melanoma and AML. Human CAR-T cells were expanded in G-Rex® 6M well plates following sorting.
What this paper found
A fully murine CAR against CD105 (endoglin) was built to study CAR-T biology in immunocompetent mice, using the B16 melanoma model. The T cells were expanded from C57BL/6J donors and activated specifically by CD105, killing CD105-positive but not CD105-negative targets in vitro. After cyclophosphamide conditioning, 3 million CAR-T cells caused rapid weight loss and a cytokine storm, whereas 500,000 cells were tolerated and engrafted at about 16-20% of circulating CD45+ cells. At this dose they slowed B16 growth and doubled survival. Tumor-infiltrating CAR-T cells showed high inhibitory receptor levels, impaired glucose uptake, lost mitochondrial mass and reduced surface CAR. A human CD105 CAR, based on carotuximab, also prolonged survival of NSG mice with melanoma or AML.
Note: Preclinical mouse and cell-line work; the authors note that the human CD105 CAR showed moderate activity and needs further optimization and safety evaluation before clinical consideration.
The murine CAR-T cells described herein are easy to produce, administer and track in vivo. — Konstantinos Lontos, Yiyang Wang, Mason Colbert, Alok Kumar, Supriya Joshi, Mary Philbin, Yupeng Wang, Andrew Frisch, Jason Lohmueller, Dayana B. Rivadeneira, Greg M. Delgoffe, OncoImmunology
Study details
- Authors
- Konstantinos Lontos, Yiyang Wang, Mason Colbert, Alok Kumar, Supriya Joshi, Mary Philbin, Yupeng Wang, Andrew Frisch, Jason Lohmueller, Dayana B. Rivadeneira, Greg M. Delgoffe
- Institution
- Tumor Microenvironment Center, Department of Immunology, UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA · Division of Hematology/Oncology, UPMC, Pittsburgh, PA, USA · School of Medicine, Tsinghua University, Beijing, Peking, China · Graduate Program of Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA · Department of Surgery, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
- Journal
- OncoImmunology
- Year
- 2022
- G-Rex® model(s)
- G-Rex®6M Well Plate
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy · Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
Human CD105-targeted CAR-T cells were expanded in a G-Rex® 6M Well Plate (Wilson Wolf). Healthy-donor T cells were isolated, activated with TransAct and 200 IU/mL human IL-2 for 48 hours, then retrovirally transduced and FACS sorted after 48 hours of incubation. The sorted cells were moved into the G-Rex® 6M Well Plate for expansion and harvested on day 10 for analysis or adoptive transfer into NSG mice.
Explore related
Full citation
Lontos K, Wang Y, Colbert M, et al. Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology. Oncoimmunology. 2022;11(1):2131229.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.